| abstract |
The invention relates to a pyrimidine derivative of formula (I"') wherein m is 1, 2 or 3; R1 is hydrogen or C1-4alkyl; R2' is cyano; X1 is -NH- or -O-; R3 is NR13R14 -C(=O)-NHR13, -C(=O)-NR13R14, -C(=O)-R15, -CH=N-NH-C(=O)-R16, C1-6alkyl substituted by NR9R10 or R7; C1-6alkyl substituted with two cyano substituents; C1-6alkyl substituted with a hydroxyl group and the second substituent is selected from cyano or R7; C1-6alkoxyC1-6alkyl optionally substituted with one cyano group; C2-6alkenyl substituted by one or two substituents independently selected from the group consisting of halogen, NR9R10, -C(=O)-NR9R10, -C(=O)-C1-6alkyl or R7; is selected from the group consisting of halogen, cyano, NR9R10, -C(=O)-NR9R10, -C(=O)-C1-6alkyl or R7, -C(=N-O-R8)-C1-4alkyl, R7 or -X3-R7 X3 is -C(=O)- or -X2-C1-4alkanediyl- R4 is f halogen, C1-6alkyl, C1-6alkoxy, nitro, amino or R7; R7 is a monocyclic or bicyclic saturated or aromatic carbocyclic group; wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two or three substituents; R8, R9 and R10 are as defined herein; a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof. The novel compounds exhibit inhibiting properties of HIV (human immunodeficiency virus) replication. Accordingly, the invention also relates to the use of the new compounds for the manufacture of a medicament for the treatment of HIV infection and to a pharmaceutical composition comprising a pyrimidine derivative of formula (I"') as an active ingredient. |